Sight Sciences, Inc. is an ophthalmic medical device company headquartered in Menlo Park, California. The company focuses on developing and commercializing surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Sight Sciences sells innovative products that empower eyecare providers to elevate standards of care and improve patients' lives by preserving their sight.
-
Surgical Glaucoma Segment - Develops and markets devices for reducing intraocular pressure in adult glaucoma patients, including the OMNI® Surgical System and SION® Surgical Instrument, which are used in ophthalmic surgical procedures.
- OMNI® Surgical System - A handheld, single-use device enabling comprehensive procedures to reduce intraocular pressure without implants.
- SION® Surgical Instrument - A bladeless, manually operated device for excising trabecular meshwork in ophthalmic surgeries.
-
Dry Eye Segment - Offers the TearCare® System, an interventional device designed to treat evaporative dry eye disease by melting and removing meibomian gland obstructions, restoring gland functionality and healthy oil production.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
David Badawi, M.D. ExecutiveBoard | Chief Technology Officer (CTO) | President of Central Eye Care Ltd | Co-founder of SGHT (2011), practicing ophthalmologist, key contributor to product development; holds an M.D. from Georgetown University and a B.S. in Microbiology from the University of Maryland. | |
Paul Badawi ExecutiveBoard | President, CEO, and Director | None | Co-founder of SGHT (2011), leads strategic vision and growth; holds an MBA from UCLA and a B.S. in Biological Sciences from the University of Chicago. | View Report → |
Alison Bauerlein Executive | Chief Financial Officer (CFO) | Board Member at Pear Therapeutics, Inc. and Koya Medical, Inc. | Joined SGHT in 2023; co-founder of Inogen, Inc., with 20+ years of financial expertise; holds a B.A. in Economics/Mathematics from UC Santa Barbara. | |
Brenton Taylor Executive | Executive Vice President, Operations | None | Joined SGHT in 2024; co-founder of Inogen, Inc., with 20+ years of operational expertise; holds a B.S. in Microbiology from UC Santa Barbara. | |
Jeremy Hayden Executive | Chief Legal Officer | None | Joined SGHT in 2020; previously General Counsel at Endologix, Cytori Therapeutics, and Volcano Corporation; holds a J.D. from the University of Michigan Law School. | |
Matthew Link Executive | Chief Commercial Officer (CCO) | Managing Partner at Orion Healthcare Advisors; Board Member at Springbok Analytics, Fibrobiologics, DinamicOR, and Coulter Translational Research Endowment | Joined SGHT in 2023; former President of NuVasive, scaled revenue to over $1 billion; holds a BSEd in Physical Education and Sports Medicine from the University of Virginia. | |
MK Raheja Executive | Executive Vice President, R&D | None | Joined SGHT in 2024; 35+ years in ophthalmology innovation; former Head of Surgical Vision R&D at Johnson & Johnson Vision; holds a Ph.D. from the University of Massachusetts and an Executive MBA from Boston University. | |
Brenda Becker Board | Director | SVP, Global Government Affairs at Boston Scientific | Director since 2022; former Assistant Secretary for Legislative Affairs at the U.S. Department of Commerce; holds a B.A. in Political Science and Public Administration from Michigan State University. | |
Catherine Mazzacco Board | Director | Board Member at Krystal Biotech, Inc. and Servier SAS | Director since 2023; former CEO of LEO Pharma; holds a B.S. in Engineering, Option Biotechnology, from the University of Compiègne, France. | |
Donald Zurbay Board | Director | CEO of Patterson Companies, Inc.; Board Member at Silk Road Medical, Inc. | Director since 2020; extensive financial leadership experience; holds a B.S. in Business Accounting from the University of Minnesota. | |
Erica Rogers Board | Director | Director at Histosonics | Director since 2019; former CEO of Silk Road Medical, Inc.; holds a B.S. in Zoology from San Diego State University. | |
Staffan Encrantz Board | Chairperson of the Board | President of Allegro Investment Inc.; Board Member at Alligator Biosciences AB | Chairperson since 2017; extensive financial and industry experience; holds a Bachelor of Law and Business Studies degree from Uppsala University, Sweden. |
-
In the third quarter, surgical glaucoma revenue growth was only 1% year-over-year, with utilization decreasing 7% sequentially and a slower-than-expected recovery from the LCD process. Given the underperformance and inconsistent recovery across territories, what specific steps are you taking to address the root causes of underperformance in your sales force, and how confident are you that these measures will lead to sustained improvement in the coming quarters?
-
With the final LCDs restricting combination MIGS procedures and estimating that approximately 10% of total MIGS codes billed are affected, how do you plan to mitigate the impact on market growth and ensure that OMNI remains competitive in a one-MIGS environment, especially considering the increased trialing of lower-priced devices during the coverage uncertainty?
-
Dry eye revenue declined 4% year-over-year but was ahead of expectations due to significant interest in purchasing TearCare Smart Lids ahead of a price increase. Given that the value creation for TearCare is tied to achieving equitable reimbursement, can you elaborate on the challenges you face in securing market access wins and the timeline for expecting meaningful contributions from this segment?
-
Despite generating $0.4 million of cash in the quarter through improvements in working capital, you acknowledged these were largely one-time benefits. With plans to invest in R&D, TearCare market access, and commercial expansion, how do you reconcile these necessary expenditures with your guidance of achieving cash flow breakeven without raising additional equity capital?
-
Given that the final 2025 Medicare payment rule did not assign device-intensive status to CPT code 66174 associated with the OMNI procedure, and the offset amount was just below the threshold at 29.14%, how significant is this setback to your ASC strategy, and what concrete actions are you taking to ensure proper device cost reporting to CMS to potentially achieve device-intensive status in the future?
Research analysts who have asked questions during Sight Sciences earnings calls.
Thomas Stephan
Stifel
4 questions for SGHT
Danielle Antalffy
UBS Group AG
3 questions for SGHT
Frank Takkinen
Lake Street Capital Markets
3 questions for SGHT
David Saxon
Needham & Company
2 questions for SGHT
Joanne Wuensch
Citigroup Inc.
2 questions for SGHT
Macauley Kilbane
William Blair & Company
2 questions for SGHT
Phillip Dantoin
Piper Sandler
2 questions for SGHT
Justin Wang
Morgan Stanley
1 question for SGHT
Kyle Winborne
Piper Sandler Companies
1 question for SGHT
Michael Arens
William Blair
1 question for SGHT
Nelson Cox
Lake Street Capital Markets
1 question for SGHT
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Develops and markets MIGS devices such as iStent technologies, iPRIME Viscodelivery System, and iDose TR intraocular implant, which are used to address glaucoma. These products are part of a competitive landscape where significant resources are dedicated to promoting and developing new treatments. | |
Competes in the MIGS market with approved products for glaucoma treatment. The company benefits from established relationships with healthcare professionals and distribution networks. | |
Operates in both the MIGS and dry eye disease markets with approved products, leveraging significant resources and established market presence. | |
New World Medical | Competes in the MIGS market with approved products for glaucoma treatment, contributing to the competitive dynamics of the industry. |
Participates in the MIGS market with approved products, adding to the competitive landscape for glaucoma treatments. | |
Competes in the dry eye disease market with approved products, leveraging its extensive resources and market presence. | |
Operates in the dry eye disease market with approved products, benefiting from its established distribution networks and relationships with healthcare professionals. | |
Competes in the dry eye disease market with approved products, alongside its presence in the MIGS market, leveraging its broad resources and market reach. |
Recent press releases and 8-K filings for SGHT.
- The MIGS market is experiencing a headwind in 2025 due to Local Coverage Determinations (LCDs) but is expected to return to growth in 2026. Sight Sciences' surgical glaucoma revenue was down mid-single digits in Q2, outperforming the 15% headwind from multiple MIGS restrictions.
- Sight Sciences is actively pursuing reimbursement for its TearCare procedure, aiming for 2025 policy wins. The company has robust clinical evidence, including a two-year randomized controlled trial (RCT) showing superiority to the standard of care and significant durability.
- TearCare addresses a large patient population, with over 19 million diagnosed and 19 million undiagnosed dry eye patients in the United States. The company has over 1,500 SmartHubs (TearCare devices) already installed with eye care providers, ready for activation upon securing reimbursement.
- Sight Sciences, Inc. is implementing a plan to reduce operating expenses and improve cost efficiencies, which includes a 20% reduction of its global workforce, impacting 43 employees.
- The company expects to incur a cash restructuring charge of approximately $2.7 million to $3.0 million and a non-cash reduction in stock-based compensation of $0.6 million to $1.0 million in the third quarter of 2025 due to the plan. These workforce reductions are expected to yield annualized savings of approximately $11.9 million.
- Matthew Link will step down as Chief Commercial Officer effective August 31, 2025.
- Sight Sciences reaffirmed its full-year 2025 revenue guidance of $72.0 million to $76.0 million and updated its adjusted operating expenses guidance for 2025 to $95 million to $99 million from the previous range of $101 million to $105 million.
- Sight Sciences reported Q1 2025 revenue of $17.5 million (a 9% decline YoY) with Surgical Glaucoma revenue at $17.1 million and Dry Eye revenue at $0.4 million .
- The company reaffirmed its full year 2025 revenue guidance of $70–$75 million .
- Strong financial performance was noted with an 86% gross margin and operating expenses reduced by 7% to $29.0 million, although a net loss of $14.2 million was reported .
- Sight Sciences improved its adjusted operating expense outlook to $101.0–$105.0 million .
- Key product development included the launch of the next-generation OMNI Edge at the ASCRS Annual Meeting .
- Ongoing discussions to secure reimbursement coverage for TearCare continue, with no coverage determinations made yet .
- Management also highlighted challenges from new Medicare restrictions and a 145% tariff rate on Chinese imports expected to increase cost of goods sold .